Tvardi Therapeutics (TVRD) Interest Expenses (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Interest Expenses of $748000.0 for Q1 2026, up 1396.0% sequentially from $50000.0 in Q4 2025, and down 86.4% YoY from $5.5 million in Q1 2025.
Tvardi Therapeutics (TVRD) Interest Expenses (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Interest Expenses for 14 years, with the latest figure at $748000.0 in Q1 2026.
- Quarterly Interest Expenses fell 86.4% year-over-year to $748000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $748000.0 (down 92.82% YoY) and the FY2025 annual result came in at $1.1 million, down 99.27% from the prior year.
- Interest Expenses grew to $748000.0 in Q1 2026 per TVRD's latest filing, from $50000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $34.1 million in Q3 2025 and troughed at $49000.0 in Q4 2024.
- A 5-year average of $4.5 million and a median of $1.4 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses sank 90.26% in 2024, then soared 13980.17% in 2025.
- Over 5 years, Interest Expenses stood at $494000.0 in 2022, then rose by 1.82% to $503000.0 in 2023, then tumbled by 90.26% to $49000.0 in 2024, then climbed by 2.04% to $50000.0 in 2025, then jumped by 1396.0% to $748000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $748000.0, $50000.0, and $34.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 748,000.00 |
| Mar 31, 2026 | 748,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 34.08 Mn |
| Sep 30, 2025 | 34.08 Mn |
| Jun 30, 2025 | 17.04 Mn |
| Jun 30, 2025 | 17.04 Mn |
| Mar 31, 2025 | 5.50 Mn |
| Mar 31, 2025 | 5.50 Mn |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 4.36 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Jun 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 121,000.00 |
| Mar 31, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 503,000.00 |
| Dec 31, 2023 | 503,000.00 |